Characteristics of amniotic fluid derived stem cells with trisomy 21.
10.5468/kjog.2010.53.9.825
- Author:
Kyung Mi CHOI
1
,
2
;
Eun Hye IM
;
Jung Ah CHO
;
Se Jin LEE
;
Ho PARK
;
Bong Shik SHIN
;
Jung Hun LEE
;
Joong Sub CHOI
;
Kyo Won LEE
Author Information
1. Department of Obstetrics and Gynecology, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea. kw
2. lee@samsung.com
- Publication Type:Original Article
- Keywords:
Amniotic fluid derived stem cell;
Down syndrome
- MeSH:
Amniocentesis;
Amniotic Fluid;
Apoptosis;
Blotting, Western;
Down Syndrome;
Female;
Genes, bcl-2;
Glial Fibrillary Acidic Protein;
Humans;
Informed Consent;
Insulin;
Microscopy, Phase-Contrast;
Microtubule-Associated Proteins;
Phosphopyruvate Hydratase;
Pregnancy;
Prenatal Diagnosis;
Proteins;
Stem Cells;
Tissue Engineering;
Trisomy
- From:Korean Journal of Obstetrics and Gynecology
2010;53(9):825-832
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
OBJECTIVE: To assess molecular markers of amniotic fluid derived stem cells (AFSCs) in aspects of increased neurological deficit in Down syndrome. METHODS: Amniotic fluid samples through amniocentesis for prenatal diagnosis from four mid trimester pregnancies; by routine chromosomal analysis, two of them were trisomy 21 (Down syndrome) and others were normal, were selected after informed consent. Cells from two-stage culture protocol were assayed; morphology through phase contrast microscopy, chromosomal analysis, reverse transcriptase-polymerase chain reaction and Western blot analysis. RESULTS: AFSCs were highly proliferative in subcultures and most of them were mononuclear, fibroblast-like, fusiform cells. There were also a few ovoid cells. The chromosomal analysis of amniotic fluid stem cells was identical to that of amniotic fluid cells. Two of four samples were 47,XX,+21, others were 46,XX. Of the proteins related to Down syndrome, the expression of S100beta were increased in AFSCs of Down syndrome, COL6A1 (Collagen IV, alpha 1) was down-regulated in them and insulin like growth factor binding protein-1 was expressed in all AFSCs. Stem cell markers were expressed heterogeneously. Oct4 (POU5F1), nanog, and SOX2 (sex determining region Y) were expressed in both groups. But c-Kit was not expressed in AFSCs of Down syndrome. The neural cell marker, neuron specific enolase was detected in both groups. Other neural cell markers, microtubule associated protein 2, glial fibrillary acidic protein were undetectable in ASFCs of Down syndrome. Bcl-2 gene family proteins related with apoptosis were assayed. The expression of Bcl-XL was increased in Down syndrome more than in normal pregnancy. Bcl-2 and BID were expressed in all AFSCs and Bax was down-regulated in Down syndrome. CONCLUSION: AFSCs are an excellent choice for many future tissue engineering strategies and cell based therapies. Analysis of molecular features of AFSCs from normal and Down syndrome will provide the basis of further experimental study.
